MedTrace Logo

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

NCT04812470 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases (including but not restricted to) of malignant melanoma.

Conditions

  • Metastatic Uveal Melanoma
  • Metastatic Cutaneous Melanoma

Interventions

DRUG

Autologous Tumor Infiltrating Lymphocytes

Administered via hepatic arterial infusion

DRUG

Melphalan

Melphalan will be administered once as an intravenous infusion.

DRUG

Interleukin-2

After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.

Sponsors & Collaborators

  • Miltenyi Biomedicine GmbH

    collaborator INDUSTRY

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Lars Ny · Department of Oncology, Sahlgrenska University Hospital, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-06
Primary Completion
2025-05-26
Completion
2025-05-26

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04812470 on ClinicalTrials.gov